{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T12:29:57Z","timestamp":1789216197289,"version":"build-2803163510"},"reference-count":105,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.cpet.2018.05.005","type":"journal-article","created":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T10:58:21Z","timestamp":1534503501000},"page":"491-503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Radionuclide Therapy for Bone Metastases"],"prefix":"10.1016","volume":"13","author":[{"given":"Hojjat","family":"Ahmadzadehfar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Essler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kambiz","family":"Rahbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Afshar-Oromieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpet.2018.05.005_bib1","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1056\/NEJMra0805239","article-title":"Molecular basis of metastasis","volume":"359","author":"Chiang","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cpet.2018.05.005_bib2","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cpet.2018.05.005_bib3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/sj.cr.7290266","article-title":"Mechanisms of cancer metastasis to the bone","volume":"15","author":"Yin","year":"2005","journal-title":"Cell Res"},{"key":"10.1016\/j.cpet.2018.05.005_bib4","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1158\/1078-0432.CCR-13-1590","article-title":"Molecular mechanisms of bone metastasis and associated muscle weakness","volume":"20","author":"Waning","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cpet.2018.05.005_bib5","doi-asserted-by":"crossref","first-page":"6213s","DOI":"10.1158\/1078-0432.CCR-06-1007","article-title":"Basic mechanisms responsible for osteolytic and osteoblastic bone metastases","volume":"12","author":"Guise","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cpet.2018.05.005_bib6","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00520-008-0418-0","article-title":"Impact of skeletal complications on patients' quality of life, mobility, and functional independence","volume":"16","author":"Costa","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.cpet.2018.05.005_bib7","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0090-4295(94)80043-X","article-title":"The use of strontium 89 for palliation of pain from bone metastases associated with hormone-refractory prostate cancer","volume":"44","author":"Crawford","year":"1994","journal-title":"Urology"},{"key":"10.1016\/j.cpet.2018.05.005_bib8","first-page":"256","article-title":"Relative efficacy of 32P and 89Sr in palliation in skeletal metastases","volume":"40","author":"Nair","year":"1999","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2018.05.005_bib9","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/MNM.0b013e32825a6adc","article-title":"A\u00a0comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases","volume":"28","author":"Liepe","year":"2007","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.cpet.2018.05.005_bib10","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/RLU.0b013e318279bf4d","article-title":"Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study","volume":"38","author":"Yuan","year":"2013","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.cpet.2018.05.005_bib11","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1089\/cbr.2014.1720","article-title":"Development of a [177Lu]BPAMD labeling kit and an automated synthesis module for routine bone targeted endoradiotherapy","volume":"30","author":"Meckel","year":"2015","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.cpet.2018.05.005_bib12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cpet.2018.05.005_bib13","series-title":"Prostate cancer - leading-edge diagnostic procedures and treatments","article-title":"Targeted therapy for metastatic prostate cancer with radionuclides","author":"Ahmadzadehfar","year":"2016"},{"key":"10.1016\/j.cpet.2018.05.005_bib14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3413\/Nukmed-0792-16-01","article-title":"Procedure guidelines for radioiodine therapy of differentiated thyroid cancer. Version 4","volume":"55","author":"Dietlein","year":"2016","journal-title":"Nuklearmedizin"},{"key":"10.1016\/j.cpet.2018.05.005_bib15","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3413\/nukmed-0311","article-title":"[Procedure guidelines for MIBG-scintigraphy in children]","volume":"47","author":"Franzius","year":"2008","journal-title":"Nuklearmedizin"},{"key":"10.1016\/j.cpet.2018.05.005_bib16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1055\/s-0037-1616480","article-title":"177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer","volume":"55","author":"Fendler","year":"2016","journal-title":"Nuklearmedizin"},{"key":"10.1016\/j.cpet.2018.05.005_bib17","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1007\/s00259-011-1902-1","article-title":"Peptide receptor radionuclide therapy with (1)(7)(7)Lu-DOTATATE: the IEO phase I-II study","volume":"38","author":"Bodei","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2018.05.005_bib18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0001-2998(05)80153-9","article-title":"Phosphorus-32 radiopharmaceuticals for the treatment of painful osseous metastases","volume":"22","author":"Silberstein","year":"1992","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.cpet.2018.05.005_bib19","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/0277-5379(91)90257-E","article-title":"A\u00a0prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone","volume":"27","author":"Lewington","year":"1991","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cpet.2018.05.005_bib20","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1259\/0007-1285-64-765-816","article-title":"Strontium-89 chloride for pain palliation in prostatic skeletal malignancy","volume":"64","author":"Laing","year":"1991","journal-title":"Br J Radiol"},{"key":"10.1016\/j.cpet.2018.05.005_bib21","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/00000421-199306000-00009","article-title":"Strontium 89 therapy and relief of pain in patients with prostatic carcinoma metastatic to bone: a dose response relationship?","volume":"16","author":"Mertens","year":"1993","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.cpet.2018.05.005_bib22","first-page":"1437","article-title":"Strontium-89 and low-dose infusion cisplatin for patients with hormone refractory prostate carcinoma metastatic to bone: a preliminary report","volume":"33","author":"Mertens","year":"1992","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2018.05.005_bib23","first-page":"349","article-title":"Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma","volume":"14","author":"Buchali","year":"1988","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.cpet.2018.05.005_bib24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000092935","article-title":"Serum hemoglobin levels predict response to strontium-89 and rhenium-186-HEDP radionuclide treatment for painful osseous metastases in prostate cancer","volume":"77","author":"van der Poel","year":"2006","journal-title":"Urol Int"},{"key":"10.1016\/j.cpet.2018.05.005_bib25","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1148\/radiographics.9.2.2467331","article-title":"Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone","volume":"9","author":"Robinson","year":"1989","journal-title":"Radiographics"},{"key":"10.1016\/j.cpet.2018.05.005_bib26","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1001\/jama.1995.03530050068035","article-title":"Strontium 89 therapy for the palliation of pain due to osseous metastases","volume":"274","author":"Robinson","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.cpet.2018.05.005_bib27","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1001\/jamaoncol.2015.5570","article-title":"Clinical outcomes and survival following treatment of metastatic castrate-refractory prostate cancer with docetaxel alone or with Strontium-89, Zoledronic Acid, or both: the TRAPEZE randomized clinical trial","volume":"2","author":"James","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cpet.2018.05.005_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20530","article-title":"TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer","volume":"20","author":"James","year":"2016","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.cpet.2018.05.005_bib29","first-page":"219","article-title":"Predictors of response to strontium-89 (Metastron) in skeletal metastases from prostate cancer: report of a single centre's 10-year experience","volume":"13","author":"Windsor","year":"2001","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.cpet.2018.05.005_bib30","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0302-2838(03)00364-6","article-title":"Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group","volume":"44","author":"Oosterhof","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.cpet.2018.05.005_bib31","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s002590100533","article-title":"A\u00a0multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer","volume":"28","author":"Dafermou","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.cpet.2018.05.005_bib32","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0360-3016(93)90309-J","article-title":"Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer","volume":"25","author":"Porter","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cpet.2018.05.005_bib33","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1046\/j.1440-1673.2001.00871.x","article-title":"Strontium-89 treatment for prostate cancer bone metastases: does a prostate-specific antigen response predict for improved survival?","volume":"45","author":"Zyskowski","year":"2001","journal-title":"Australas Radiol"},{"issue":"Suppl 1","key":"10.1016\/j.cpet.2018.05.005_bib34","first-page":"38S","article-title":"Bone-seeking radionuclides for therapy","volume":"46","author":"Lewington","year":"2005","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2018.05.005_bib35","first-page":"1877","article-title":"Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo","volume":"32","author":"Maxon","year":"1991","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2018.05.005_bib36","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1055\/s-0038-1632262","article-title":"Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases","volume":"39","author":"Liepe","year":"2000","journal-title":"Nuklearmedizin"},{"key":"10.1016\/j.cpet.2018.05.005_bib37","first-page":"647","article-title":"Short- and long-term effects of 186Re-1,1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases","volume":"41","author":"Sciuto","year":"2000","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2018.05.005_bib38","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/sj.bjc.6600348","article-title":"High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone","volume":"86","author":"O'Sullivan","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cpet.2018.05.005_bib39","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3413\/Nukmed-0828-16-05","article-title":"Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP. Clinical benefit in a real-world study","volume":"55","author":"Lange","year":"2016","journal-title":"Nuklearmedizin"},{"key":"10.1016\/j.cpet.2018.05.005_bib40","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1089\/108497800414356","article-title":"Rhenium-188-HEDP in the palliative treatment of bone metastases","volume":"15","author":"Liepe","year":"2000","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.cpet.2018.05.005_bib41","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1200\/JCO.2003.12.060","article-title":"Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate","volume":"21","author":"Palmedo","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpet.2018.05.005_bib42","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.2967\/jnumed.111.093674","article-title":"Palliation and survival after repeated (188)Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis","volume":"52","author":"Biersack","year":"2011","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2018.05.005_bib43","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s002590050017","article-title":"Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases","volume":"27","author":"Palmedo","year":"2000","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.cpet.2018.05.005_bib44","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00259-017-3673-9","article-title":"A\u00a0randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial","volume":"44","author":"van Dodewaard-de Jong","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2018.05.005_bib45","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/sj.bjc.6601158","article-title":"Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases","volume":"89","author":"Liepe","year":"2003","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.cpet.2018.05.005_bib46","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00520-017-3885-3","article-title":"Efficacy and safety of 153Sm-EDTMP as treatment of painful bone metastasis: a large single-center study","volume":"26","author":"Kolesnikov-Gauthier","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.cpet.2018.05.005_bib47","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s002590050351","article-title":"Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China","volume":"26","author":"Tian","year":"1999","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.cpet.2018.05.005_bib48","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.urology.2004.01.034","article-title":"Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer","volume":"63","author":"Sartor","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.cpet.2018.05.005_bib49","first-page":"27","article-title":"Treatment efficacy of (153)Sm-EDTMP for painful bone metastasis","volume":"1","author":"Ayati","year":"2013","journal-title":"Asia Ocean J Nucl Med Biol"},{"issue":"1","key":"10.1016\/j.cpet.2018.05.005_bib50","first-page":"21","article-title":"Efficacy and toxicity of Sm-153 EDTMP in the palliative treatment of painful bone metastases","volume":"1","author":"Enrique","year":"2002","journal-title":"World J Nucl Med"},{"key":"10.1016\/j.cpet.2018.05.005_bib51","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/MNM.0000000000000023","article-title":"Safety and antitumor efficacy of (153)Sm-EDTMP and docetaxel administered sequentially to patients with metastatic castration-resistant prostate cancer","volume":"35","author":"Borso","year":"2014","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.cpet.2018.05.005_bib52","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1002\/cncr.28103","article-title":"Repetitively dosed docetaxel and (1)(5)(3)samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer","volume":"119","author":"Autio","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.cpet.2018.05.005_bib53","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2008.18.9811","article-title":"Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer","volume":"27","author":"Fizazi","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpet.2018.05.005_bib54","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.urolonc.2009.10.003","article-title":"Phase I trial with a combination of docetaxel and (1)(5)(3)Sm-lexidronam in patients with castration-resistant metastatic prostate cancer","volume":"29","author":"Lin","year":"2011","journal-title":"Urol Oncol"},{"key":"10.1016\/j.cpet.2018.05.005_bib55","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(16)30173-5","article-title":"Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial","volume":"17","author":"Saad","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cpet.2018.05.005_bib56","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s00259-017-3652-1","article-title":"Safety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumour","volume":"44","author":"Yordanova","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2018.05.005_bib57","doi-asserted-by":"crossref","first-page":"12477","DOI":"10.18632\/oncotarget.7245","article-title":"Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer","volume":"7","author":"Ahmadzadehfar","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.cpet.2018.05.005_bib58","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2967\/jnumed.115.161299","article-title":"The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET\/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions","volume":"56","author":"Afshar-Oromieh","year":"2015","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2018.05.005_bib59","first-page":"108","article-title":"Radiolabeling and evaluation of two 177Lu-labeled bis-phosphonates","volume":"23","author":"Fakhari","year":"2015","journal-title":"Iran J Nucl Med"},{"key":"10.1016\/j.cpet.2018.05.005_bib60","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4103\/1450-1147.157124","article-title":"Metastatic bone pain palliation using (177)Lu-ethylenediaminetetramethylene phosphonic acid","volume":"14","author":"Alavi","year":"2015","journal-title":"World J Nucl Med"},{"key":"10.1016\/j.cpet.2018.05.005_bib61","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00259-014-2862-z","article-title":"(177)Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study","volume":"42","author":"Agarwal","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2018.05.005_bib62","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1046\/j.1440-1673.1999.00716.x","article-title":"Strontium and samarium therapy for bone metastases from prostate carcinoma","volume":"43","author":"Dickie","year":"1999","journal-title":"Australas Radiol"},{"key":"10.1016\/j.cpet.2018.05.005_bib63","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/MNM.0b013e32805b72a0","article-title":"89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma","volume":"28","author":"Baczyk","year":"2007","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.cpet.2018.05.005_bib64","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s00432-004-0625-0","article-title":"The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain","volume":"131","author":"Liepe","year":"2005","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.cpet.2018.05.005_bib65","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3389\/fmed.2017.00046","article-title":"Comparative therapeutic efficacy of 153Sm-EDTMP and 177Lu-EDTMP for bone pain palliation in patients with skeletal metastases: patients' pain score analysis and personalized dosimetry","volume":"4","author":"Sharma","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.cpet.2018.05.005_bib66","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.2967\/jnumed.115.155762","article-title":"Clinical efficacy and\u00a0safety comparison of 177Lu-EDTMP with 153Sm-EDTMP on an equidose basis in patients with painful skeletal metastases","volume":"56","author":"Thapa","year":"2015","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2018.05.005_bib67","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa1213755","article-title":"Radium-223 in prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cpet.2018.05.005_bib68","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1517\/13543784.2013.761974","article-title":"Radium-223 for the treatment of prostate cancer","volume":"22","author":"Hafeez","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.cpet.2018.05.005_bib69","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1667\/RR0813.1","article-title":"Effect of linear energy transfer (LET) on the complexity of alpha-particle-induced chromosome aberrations in human CD34+ cells","volume":"167","author":"Anderson","year":"2007","journal-title":"Radiat Res"},{"key":"10.1016\/j.cpet.2018.05.005_bib70","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/pros.23180","article-title":"Chemotherapy following radium-223 dichloride treatment in ALSYMPCA","volume":"76","author":"Sartor","year":"2016","journal-title":"Prostate"},{"key":"10.1016\/j.cpet.2018.05.005_bib71","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/annonc\/mdw065","article-title":"Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study","volume":"27","author":"Nilsson","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cpet.2018.05.005_bib72","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1158\/1078-0432.CCR-04-2244","article-title":"First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases","volume":"11","author":"Nilsson","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cpet.2018.05.005_bib73","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1470-2045(07)70147-X","article-title":"Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study","volume":"8","author":"Nilsson","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cpet.2018.05.005_bib74","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eururo.2012.09.008","article-title":"A\u00a0randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer","volume":"63","author":"Parker","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.cpet.2018.05.005_bib75","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00259-015-3150-2","article-title":"Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride","volume":"43","author":"Pacilio","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2018.05.005_bib76","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1093\/annonc\/mdx331","article-title":"Re-treatment with radium-223: first experience from an international, open-label, phase I\/II study in patients with castration-resistant prostate cancer and bone metastases","volume":"28","author":"Sartor","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cpet.2018.05.005_bib77","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s00259-015-3185-4","article-title":"Factors affecting (223)Ra therapy: clinical experience after 532 cycles from a single institution","volume":"43","author":"Etchebehere","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.cpet.2018.05.005_bib78","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2967\/jnumed.117.195677","article-title":"Radium-223 therapy of advanced metastatic castration-resistant prostate cancer: quantitative assessment of skeletal tumor burden for prognostication of clinical outcome and hematological toxicity","volume":"59","author":"Fosbol","year":"2018","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2018.05.005_bib79","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.2967\/jnumed.115.156026","article-title":"Determination of skeletal tumor burden on 18F-Fluoride PET\/CT","volume":"56","author":"Rohren","year":"2015","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2018.05.005_bib80","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.2967\/jnumed.115.158626","article-title":"Prognostic factors in patients treated with 223Ra: the role of skeletal tumor burden on baseline 18F-Fluoride PET\/CT in predicting overall survival","volume":"56","author":"Etchebehere","year":"2015","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2018.05.005_bib81","doi-asserted-by":"crossref","first-page":"5470","DOI":"10.1002\/cncr.24599","article-title":"Detection of hematogenous bone metastasis in cervical cancer: 18F-fluorodeoxyglucose-positron emission tomography versus computed tomography and magnetic resonance imaging","volume":"115","author":"Liu","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.cpet.2018.05.005_bib82","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/annonc\/mdn057","article-title":"Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer","volume":"19","author":"Mahner","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cpet.2018.05.005_bib83","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.oraloncology.2007.01.011","article-title":"18F-fluorodeoxyglucose-positron emission tomography and bone scintigraphy for detecting bone metastases in patients with malignancies of the upper aerodigestive tract","volume":"44","author":"Kim","year":"2008","journal-title":"Oral Oncol"},{"key":"10.1016\/j.cpet.2018.05.005_bib84","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cpet.2010.04.001","article-title":"FDG PET for the detection of bone metastases: sensitivity, specificity and comparison with other imaging modalities","volume":"5","author":"Costelloe","year":"2010","journal-title":"PET Clin"},{"key":"10.1016\/j.cpet.2018.05.005_bib85","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.ejrad.2011.01.126","article-title":"A\u00a0meta-analysis of (1)(8)FDG-PET-CT, (1)(8)FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer","volume":"81","author":"Qu","year":"2012","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.cpet.2018.05.005_bib86","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1200\/JCO.1998.16.10.3375","article-title":"Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions","volume":"16","author":"Cook","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpet.2018.05.005_bib87","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1007\/s00259-006-0141-3","article-title":"FDG-PET and CT patterns of bone metastases and their relationship to previously administered anti-cancer therapy","volume":"33","author":"Israel","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2018.05.005_bib88","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/MNM.0000000000000387","article-title":"18F-FDG-PET\/MR increases diagnostic confidence in detection of bone metastases compared with 18F-FDG-PET\/CT","volume":"36","author":"Samarin","year":"2015","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.cpet.2018.05.005_bib89","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10549-004-3291-7","article-title":"A\u00a0meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases","volume":"90","author":"Isasi","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.cpet.2018.05.005_bib90","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/RLU.0b013e31815f23b7","article-title":"Meta-analysis: comparison of F-18 Fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastases in patients with breast cancer","volume":"33","author":"Shie","year":"2008","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.cpet.2018.05.005_bib91","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.suronc.2013.01.002","article-title":"Comparison of 18 FDG PET-CT and bone scintigraphy for detection of bone metastases in breast cancer patients. A meta-analysis","volume":"22","author":"Rong","year":"2013","journal-title":"Surg Oncol"},{"key":"10.1016\/j.cpet.2018.05.005_bib92","doi-asserted-by":"crossref","first-page":"e3753","DOI":"10.1097\/MD.0000000000003753","article-title":"Effectiveness of 18F-FDG-PET\/CT vs bone scintigraphy in treatment response assessment of bone metastases in breast cancer","volume":"95","author":"Al-Muqbel","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cpet.2018.05.005_bib93","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0090-4295(02)01509-1","article-title":"Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer","volume":"59","author":"Morris","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.cpet.2018.05.005_bib94","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1148\/radiology.199.3.8638000","article-title":"Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose","volume":"199","author":"Shreve","year":"1996","journal-title":"Radiology"},{"key":"10.1016\/j.cpet.2018.05.005_bib95","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/0969-8051(96)00044-3","article-title":"Detection of bony metastases of androgen-independent prostate cancer by PET-FDG","volume":"23","author":"Yeh","year":"1996","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.cpet.2018.05.005_bib96","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","article-title":"The diagnostic value of PET\/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer","volume":"42","author":"Afshar-Oromieh","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2018.05.005_bib97","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00259-012-2069-0","article-title":"[68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH","volume":"39","author":"Afshar-Oromieh","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2018.05.005_bib98","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00259-017-3711-7","article-title":"Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET\/CT in patients with recurrent prostate cancer: evaluation in 1007 patients","volume":"44","author":"Afshar-Oromieh","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2018.05.005_bib99","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3413\/Nukmed-0846-16-09","article-title":"Diagnostic value of additional 68Ga-PSMA-PET before 223Ra-dichloride therapy in patients with metastatic prostate carcinoma","volume":"56","author":"Br\u00e4uer","year":"2017","journal-title":"Nuklearmedizin"},{"key":"10.1016\/j.cpet.2018.05.005_bib100","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2967\/jnumed.116.178533","article-title":"68Ga-PSMA-11 PET as a gatekeeper for the treatment of metastatic prostate cancer with 223Ra: proof of concept","volume":"58","author":"Ahmadzadehfar","year":"2017","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2018.05.005_bib101","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1097\/RLU.0000000000000993","article-title":"Molecular and functional imaging of bone metastases in breast and prostate cancers: an overview","volume":"41","author":"Azad","year":"2016","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.cpet.2018.05.005_bib102","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/RLU.0000000000001286","article-title":"68Ga-PSMA-11 PET represents the tumoricidal effect of 223Ra in a patient with castrate-resistant metastatic prostate cancer","volume":"41","author":"Ahmadzadehfar","year":"2016","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.cpet.2018.05.005_bib103","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1097\/RLU.0b013e318292f35c","article-title":"Antitumor effect of 89Sr for multiple bone metastases of breast cancer: diagnosis by 18F-FDG PET\/CT","volume":"39","author":"Hama","year":"2014","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.cpet.2018.05.005_bib104","doi-asserted-by":"crossref","first-page":"268","DOI":"10.2967\/jnumed.112.112482","article-title":"Bone-seeking radiopharmaceuticals for treatment of osseous metastases, Part 1: alpha therapy with 223Ra-dichloride","volume":"55","author":"Pandit-Taskar","year":"2014","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2018.05.005_bib105","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1080\/02841860310014895","article-title":"A\u00a0systematic overview of radiation therapy effects in skeletal metastases","volume":"42","author":"Falkmer","year":"2003","journal-title":"Acta Oncol"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859818300671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859818300671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T09:31:00Z","timestamp":1571736660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859818300671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":105,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1556859818300671"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2018.05.005","relation":{},"ISSN":["1556-8598"],"issn-type":[{"value":"1556-8598","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radionuclide Therapy for Bone Metastases","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2018.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}